CytRx (CYTR) announces the dosing of the first patient in a Phase 2 study of aldoxorubicin in unresectable GBM.
Preliminary results expected in H2.
The company says that if the results are positive, CYTR "will pursue the rapid development of aldoxorubicin for unresectable GBM, including filing for breakthrough therapy designation." (PR)
CYTR +5% premarket.